BioSpace News Archive

CareDx, Inc. announced its partnership with MOTTEP to help advance its mission of increasing the number of minority-donated organs and greater adoption of disease prevention behaviors which reduce the incidence of end-stage disease and the need for organ transplantation in high-risk, underserved communities.

Medison is proud to announce the joining of Victor Papamoniodis in the newly created position of VP International Markets.

Pharma Two B Ltd. today announced that it will host a key opinion leader (KOL) event to discuss the positive results from the pivotal Phase III Study of P2B001 in early Parkinson’s Disease (PD) on Thursday, January 27, 2022 from 11am – 12pm Eastern Time.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities’ 2022 Oncology Conference.

Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-868.

CASI Pharmaceuticals, Inc. announced today, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its partner BioInvent International AB, for BI-1206, an investigational anti-FcyRllB antibody, for the treatment of follicular lymphoma (FL), the most common form of slow-growing Non-Hodgkin lymphoma (NHL).

Transgene and BioInvent International AB jointly announced the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.

BioInvent International AB and Transgene jointly announce the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.

Immunovia AB announces that Philipp Mathieu has been appointed acting CEO and President with immediate effect.

ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, announced the closing of a $75 million Series B financing.